Skip to main content

Amryt Pharma PLC (AMYT)

NASDAQ: AMYT · IEX Real-Time Price · USD
12.02 -0.22 (-1.80%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap771.36M
Revenue (ttm)203.04M
Net Income (ttm)-80.80M
Shares Out63.30M
EPS (ttm)-2.39
PE Ration/a
Forward PE13.77
Dividendn/a
Ex-Dividend Daten/a
Volume97,784
Open12.14
Previous Close12.24
Day's Range11.85 - 12.25
52-Week Range9.55 - 15.44
Betan/a
Analystsn/a
Price Target32.60 (+171.2%)
Est. Earnings DateNov 3, 2021

About AMYT

Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate, which is in Phase 3 EASE trial for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 that is in preclinica...

IndustryDrug Manufacturers-Specialty & Generic
Founded2015
Employees182
Stock ExchangeNASDAQ
Ticker SymbolAMYT
Full Company Profile

Financial Performance

In 2020, Amryt Pharma's revenue was $182.61 million, an increase of 214.17% compared to the previous year's $58.12 million. Losses were -$104.53 million, 65.9% more than in 2019.

Financial Statements

News

Amryt Raises Full Year 2021 Revenue Guidance to $220M - $225M

Amryt Raises Full Year 2021 Revenue Guidance to $220M - $225M

1 week ago - GlobeNewsWire

Director/PDMR Shareholding

Director / PDMR Disclosure

1 month ago - GlobeNewsWire

Amryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT

Amryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT

1 month ago - GlobeNewsWire

Amryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance

Amryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance

1 month ago - GlobeNewsWire

Result of General Meetings

DUBLIN, Ireland, and Boston MA, July 28, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatmen...

1 month ago - GlobeNewsWire

Amryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6

Amryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6

2 months ago - GlobeNewsWire

Publication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual ...

Publication of Circular to Amryt S hareholders in relation to the acquisition of Chiasma, Inc . , and p osting of Annual Report and Notice s of General Meeting s

2 months ago - GlobeNewsWire

Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acqui...

Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.

3 months ago - GlobeNewsWire

Amryt Pharma Oleogel-S10 appllcation won't go through advisory committee

Amryt Pharma PLC (NASDAQ:AMYT LON:AMYT) said the US Food and Drug Administration had confirmed its New Drug Application (NDA) for Oleogel-S10 does not require an Advisory Committee meeting.   Oleogel-S1...

3 months ago - Proactive Investors

FDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting

FDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting

3 months ago - GlobeNewsWire

Amryt (AMYT) NDA for Skin Disorder Drug Gets Priority Review

Amryt (AMYT) is seeking approval for Oleogel-S10 as a potential treatment for patients with rare and distressing genetic skin disorder, epidermolysis bullosa.

3 months ago - Zacks Investment Research

Amryt Pharma's Oleogel-S10 Application Gets FDA Priority Review Tag for Skin Blistering Disorder

The FDA has granted priority review status to Amryt Pharma's (NASDAQ: AMYT) marketing application seeking approval for Oleogel-S10 to treat Epidermolysis Bullosa (EB). Oleogel-S10 is a potential treatme...

3 months ago - Benzinga

Amryt Pharma new drug application for rare skin condition fast-tracked by US Food & Drug Administration

Amryt Pharma PLC (NASDAQ:AMYT; AIM:AMYT) was granted a priority review of its new drug application for Oleogel-S10 by the US Food & Drug Administration with a decision expected on or before November 30....

3 months ago - Proactive Investors

Amryt Pharma new drug application for rare skin condition fast-tracked by the US Food & Drug Administration

Amryt Pharma PLC (NASDAQ:AMYT; AIM:AMYT) has been granted a priority review of its new drug application for Oleogel-S10 by the US drugs watchdog with a decision expected on or before November 30. The US...

3 months ago - Proactive Investors

FDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa

FDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa

3 months ago - GlobeNewsWire

Amryt Pharma advancing on multiple fronts

What the company does Amryt Pharma PLC (LON:AMYT) sells and develops orphan drugs used to treat rare diseases with two products on the market. Last year, Amryt acquired US group Aegerion Pharmaceuticals...

3 months ago - Proactive Investors

Amryt Pharma gets FDA approval for new drug application

Amryt Pharma PLC's (NASDAQ:AMYT, LON:AMYT) new drug application for its potential treatment for epidermolysis bullosa (EB) has been approved by the US regulator. The Food and Drug Administration (FDA) a...

3 months ago - Proactive Investors

CHIASMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of P...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Chiasma, Inc. (Nas...

4 months ago - Business Wire

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Chiasma, Inc.

NEW YORK, May 5, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Chiasma, Inc. (NASDAQ: CHMA) and its board of directors concerning the proposed acquisition ...

4 months ago - PRNewsWire

SHAREHOLDER ALERT: WeissLaw LLP Investigates Chiasma, Inc.

NEW YORK, May 5, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Chiasma, Inc. ("Chiasma" or the "Company"...

4 months ago - PRNewsWire

Amryt Pharma to merge with Chiasma and create rare diseases powerhouse

Amryt Pharma PLC (LON:AMYT NASDAQ:AMYT)  is to merge with fellow Nasdaq-listed biotech Chiasma Inc (NASDAQ:CHMA) through an all-share deal that will create a leading specialist in rare and orphan diseas...

4 months ago - Proactive Investors

Amryt Reports Record Q1 2021 Financial and Operating Results

A mryt R e ports Record Q1 2021 Financial and Operating Results

4 months ago - GlobeNewsWire

Amryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases

- Combined business will have three approved commercial products , lomitapide ( Lojuxta ®/ Juxtapid ®), metreleptin ( Myalept ®/ Myalepta ®) , octreotide ( MYCAPSSA ®) and a robust clinical pipeline

4 months ago - GlobeNewsWire

Amryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5

DUBLIN, Ireland, and Boston MA, April 15, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatme...

5 months ago - GlobeNewsWire

Amryt Announces the Appointment of Sheila Frame as President Americas

DUBLIN, Ireland, and Boston MA, April 6, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatmen...

5 months ago - GlobeNewsWire